Mehta K, Haffty B G
Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT 06520, USA.
Int J Radiat Oncol Biol Phys. 1996 Jul 1;35(4):679-85. doi: 10.1016/0360-3016(96)00015-6.
The purpose of this study was to review management strategies with respect to systemic therapy, radiation therapy treatment techniques, and patient outcome (local regional control, distant metastases, and overall survival) in patients undergoing conservative surgery and radiation therapy (CS + RT) who had four or more lymph nodes involved at the time of original diagnosis.
Of 1040 patients undergoing CS + RT at our institution prior to December 1989, 579 patients underwent axillary lymph node dissection. Of those patients undergoing axillary lymph node dissection, 167 had positive nodes and 51 of these patients had four or more positive lymph nodes involved and serve as the patient population base for this study. All patients received radiation therapy to the intact breast using tangential fields with subsequent electron beam boost to the tumor bed to a total median dose of 64 Gy. The majority of patients received regional nodal irradiation as follows: 40 patients received RT to the supraclavicular region without axilla to a median dose of 46 Gy, 10 patients received radiation to the supraclavicular region and axilla to a median dose of 46 Gy. Thirty of the 51 patients received a separate internal mammary port with a mixed beam of photons and electrons. One patient received radiation to the tangents alone without regional nodal irradiation. Adjuvant systemic therapy was used in 49 of the 51 patients (96%) with 27 patients receiving chemotherapy alone, 14 patients receiving cytotoxic chemotherapy and tamoxifen, and 8 patients receiving tamoxifen alone.
As of December 1994, with a minimum evaluable follow-up of 5 years and a median follow-up of 9.29 years, there have been 18 distant relapses, 2 nodal relapses, and 5 breast relapses. Actuarial statistics reveal a 10-year distant metastases-free rate of 65%, 10-year nodal recurrence-free rate of 96%, and a 10-year breast recurrence-free rate of 82%. All five patients who sustained a breast relapse were successfully salvaged with mastectomy. Both patients with nodal relapses (one supraclavicular and one axillary/supraclavicular) failed within the irradiated volume. Of the 40 patients treated to the supraclavicular fossa (omitting complete axillary radiation), none failed in the dissected axilla. With a median follow-up of nearly 10 years, 29 of the 51 patients (57%) remain alive without evidence of disease, 15 (29%) have died with disease, 2 (4%) remain alive with disease, and 5 (10%) have died without evidence of disease. Overall actuarial 10-year survival for these 51 patients is 58%.
We conclude that in patients found to have four or more positive lymph nodes at the time of axillary lymph node dissection, conservative surgery followed by radiation therapy to the intact breast with appropriate adjuvant systemic therapy results in a reasonable long-term survival with a high rate of local regional control. Omission of axillary radiation in this subset of patients appears appropriate because there were no axillary failures among the 41 dissected but unirradiated axillae.
本研究旨在回顾对初始诊断时伴有4个或更多受累淋巴结、接受保乳手术及放疗(CS + RT)患者的全身治疗、放射治疗技术及患者预后(局部区域控制、远处转移和总生存率)的管理策略。
1989年12月前在我院接受CS + RT的1040例患者中,579例行腋窝淋巴结清扫术。在这些接受腋窝淋巴结清扫术的患者中,167例有阳性淋巴结,其中51例有4个或更多阳性受累淋巴结,作为本研究的患者群体基础。所有患者均采用切线野对完整乳房进行放射治疗,随后对瘤床给予电子束加量,总中位剂量为64 Gy。大多数患者接受区域淋巴结照射如下:40例患者接受锁骨上区放疗(未照射腋窝),中位剂量为46 Gy;10例患者接受锁骨上区及腋窝放疗,中位剂量为46 Gy。51例患者中有30例接受了单独的内乳野照射,采用光子和电子混合线束。1例患者仅接受切线野放疗,未进行区域淋巴结照射。51例患者中有49例(96%)接受了辅助全身治疗,其中27例仅接受化疗,14例接受细胞毒性化疗和他莫昔芬,8例仅接受他莫昔芬。
截至1994年12月,最小可评估随访时间为5年,中位随访时间为9.29年,发生远处复发18例、淋巴结复发2例、乳腺复发5例。精算统计显示,10年无远处转移率为65%,10年无淋巴结复发率为96%,10年无乳腺复发率为82%。所有5例乳腺复发患者均通过乳房切除术成功挽救。2例淋巴结复发患者(1例锁骨上复发,1例腋窝/锁骨上复发)在照射野内复发。在40例接受锁骨上窝放疗(未进行完整腋窝放疗)的患者中,解剖的腋窝均未复发。中位随访近10年,51例患者中有29例(57%)仍存活且无疾病证据,15例(29%)死于疾病,2例(4%)带瘤存活,5例(10%)无疾病证据死亡。这51例患者的总体精算10年生存率为58%。
我们得出结论,对于腋窝淋巴结清扫时发现有4个或更多阳性淋巴结的患者,保乳手术后对完整乳房进行放疗并给予适当的辅助全身治疗,可获得合理的长期生存率及较高的局部区域控制率。在这部分患者中省略腋窝放疗似乎是合适的,因为在41个解剖但未照射的腋窝中未出现腋窝复发。